期刊文献+

MDM2-p53通路在肺腺癌中的表达及其调控机制 被引量:3

下载PDF
导出
摘要 目的探讨MDM2蛋白、p53在肺腺癌中的表达和意义,分析MDM2、p53的表达与肺腺癌细胞增殖与凋亡的关系,探讨p53-MDM2通路在肺腺癌发生发展中的作用。方法应用免疫组化技术检测41例肺腺癌组织中PCNA、MDM2、p53的表达,同时通过TUNEL法检测肺腺癌细胞凋亡,对增殖和凋亡进行定量。结果 MDM2、p53在肺腺癌中的表达率分别为31.71%(13/41),53.66%(22/41);原发灶≥3.0 cm者,p53表达较高,MDM2较低。p53高表达与PCNA有关,与凋亡标记指数(ALI)无关。MDM2的表达与PCNA和ALI无关。MDM2表达与突变型p53表达存在相关性(r=-0.54,P<0.05)。结论 MDM2的表达与p53的表达存在负相关,是肺腺癌高度恶性的生物学标志。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2011年第17期3256-3257,共2页 Chinese Journal of Gerontology
  • 相关文献

参考文献10

  • 1Vogelstein B,l,ane D, Levine AJ. Surfing the P53 net work [J]. Nature, 2000 ;408:307-10.
  • 2Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis[J]. PNAS,2003 ; 100:8424-9.
  • 3Achison M, Hupp TR. Hypoxia attenuates the p53 response to cellular damage [J]. Oncogene ,2003 ;22 : 3431-40,.
  • 4Buschmann T, Fuchs SY, Lee Cg, et al. SUMO-1 modification of MDM2 prevents its seff-ubiquitination and increases Mdm2 ability to ubiquitinate p53 [J]. Cell ,2000 ;101:753-62.
  • 5Chne P. Inhibiting the p53-mdm2 interaction: an important target for cancer therapy[J]. Nat Rev Cancer,2003 ;3 (2) : 102-9.
  • 6Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein [J]. Curr Opin Cell Biol,2001 ; 13 ( 3 ) : 332-7.
  • 7Lahav G, Rosenfeld N, Sigal A, et al. Dynamics of the p53-MDM2 feed-back loop in individual cells [J]. Nat Genet,2004 ;36 ( 2 ) : 147-50.
  • 8Martha L, Simmon S, Kathleen R ,et al. Analysis of complex relationships between age,p53,epidermal growth factor receptor, and survival in glioblastoma patients[J]. Cancer Res ,2001 ;61 : 1122-8.
  • 9孙艳花,钟雪云,陈运贤,关弘.星形细胞瘤中Mdm2、p53的表达及调控机制探讨[J].肿瘤防治研究,2004,31(8):477-479. 被引量:14
  • 10LeBron C,Chen L, Gilkes DM, et al. Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3 [J]. EMBO J, 2006; 2225 (6) : 1196-206.

二级参考文献9

  • 1Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein[J].Cell Mol Life Sci, 1999,55(1):96-107.
  • 2Sarkar C, Ralte AM, Sharma MC, et al. Recurrent astrocytic tumours-a study of p53 immunoreactivity and malignant progression[J].Br J Neurosurg, 2002,16(4):335-342.
  • 3Fult D, Brockmeyer D, Tullous MW, et al. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression[J].Cancer Res, 1992,52(3):674-679.
  • 4Michael D , Oren M. The p53-Mdm2 module and the ubiquitin system[J].Semin Cancer Biol,2003,13(1):49-58.
  • 5Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2[J].Nature, 1997, 387(6630):299-303.
  • 6Mayo LD , Dixon JE , Durden DL , et al. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy[J].J Biol Chem, 2002,277(7):5484-5489.
  • 7Chène P . Inhibiting the p53-MDM2 interaction : an important target for cancer therapy[J]. Nat Rev Cancer, 2003,3(2):102-109.
  • 8孙艳花,钟雪云.PTEN与信号转导及肿瘤[J].中国病理生理杂志,2002,18(3):326-329. 被引量:7
  • 9浣孝强,孟斌,邓卓霖,缪勇建.MDM2、p53和p21^(WAF1/CIP1)蛋白在胃癌中的表达及意义[J].广西医科大学学报,2002,19(1):35-38. 被引量:6

共引文献13

同被引文献60

  • 1马良赟,伍硕允,叶敏,陈志锦,庞文广.非小细胞肺癌临床和外科病理分期的比较[J].中国综合临床,2004,20(8):717-719. 被引量:4
  • 2任义,吴逸明,董海燕,魏立,吴拥军.肺癌组织中MDM2、P53蛋白的表达[J].郑州大学学报(医学版),2005,40(1):67-69. 被引量:9
  • 3孙迎娟,时飞,孙坚萍,黄葆华,罗兵.胃癌组织中p53基因突变及p53和mdm2蛋白表达的研究[J].肿瘤防治杂志,2005,12(13):974-978. 被引量:11
  • 4高崇峰,吕有勇.胃癌组织中多种癌基因变异的观察[J].中华医学杂志,1996,76(9):671-675. 被引量:10
  • 5Fendrich V,Waldmann J, Feldmann G, et al. Unique expression pattern of the EMT markers Snail,Twist and E-cadherin in benign and malignant parathyroid neoplasia. Eur J Endocrinol, 2009, 160 (4) : 695 -703.
  • 6Yuen H F, Chua C W, Chan Y P, et al. Significance of Twist and E-cadherin expression in the metastatic progression of prostate cancer. Histopathology, 2007,50 ( 5 ) :648-658.
  • 7Tandon S, Beer H, Jones TM, et al. Immunohistochemical expression of p53 and MDM2 within head and neck squamous cell carcinoma[ J]. Clin Otolaryngol, 2006,31 ( 3 ) :247.
  • 8Lam KY, LO CY, Wat NM. The clinicopathological features and import ance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas[ J]. J Clin Pathol, 2001,54(6) :443 -448.
  • 9Wang M, Zhang Z, Zhu H, et al. A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population[ J]. Clin Cancer Res, 2008,14 ( 11 ) : 3633 - 3640.
  • 10Epistolato MC, Diseiglio V, Livide G, et al. p53 Arg72Pro and MDM2 309 SNPs in hereditary retinoblastoma[ J]. J Hum Genet, 2011,56 (9) :685 -686.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部